Dana Farber Cancer Institute

Site:	Dana Farber Cancer Institute	Go to their website
Address:	450 Brookline Ave
City:	Boston
State:	MA
Zip:	02215-5450
Country:	USA

74 trials at this site

Phase [asc]	Trial	Trial Status	Site Status	Drug	NCT#
2	Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors	Completed	Closed	Imatinib + RAD001	NCT01275222
2	A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST	Completed	Closed	Imatinib + AT13387	NCT01294202
2	A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors	Terminated	Closed	Olaratumab (IMC-3G3)	NCT01316263
2	Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors	Completed	Not yet activated	Linsitinib (OSI-906)	NCT01560260
2	Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)	Terminated	Closed	Pazopanib (Votrient)	NCT01391611
2	A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor	Completed	Closed	Sunitinib	NCT01396148
2	A Phase 2 Trial of Ponatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor	Completed	Closed	Ponatinib (Iclusig)	NCT01874665
2	Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic or Unresectable Sarcoma	Completed	Closed	Nivolumab + Ipilimumab	NCT02500797
2	Study of LOXO-101 in Subjects With NTRK Fusion Positive Solid Tumors	Active, not recruiting	Active, not recruiting	LOXO-101	NCT02576431
2	Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study	Active, not recruiting	Closed	CB-839	NCT03872427
2	Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Active, not recruiting	Closed	Rogaratinib	NCT04595747
2	Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor	Completed	Closed	Temozolomide	NCT03556384
2	SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST	Active, not recruiting	Closed	Bezuclastinib plus Sunitinib	NCT06208748
2	M6620 (VX-970) in Selected Solid Tumors	Completed	Closed	Berzosertib	NCT03718091
2	PEMIGIST: Phase 2 Study of Pemigatinib (INCB054828) in the Treatment of Patients With Advanced SDH-deficient Gastrointestinal Stromal Tumor (GIST)	Recruiting	Active	Pemigatinib	NCT07434843
2	KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting	Recruiting	Not yet activated	KQB198 + Imatinib	NCT07406633
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib (ENEST)	Completed	Closed	Nilotinib	NCT00471328
3	Study of IPI-504 in GIST patients following failure of at least imatinib and sunitinib	Terminated	Closed	IPI-504	NCT00688766
3	Efficacy and Safety of AMN107 Compared With Current Treatment Options in Patients With GIST Who Have Failed Both Imatinib and Sunitinib - Extension	Completed	Closed	Nilotinib	NCT00488150
3	A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumors (Gist)	Completed	Closed	Sunitinib	NCT00075218

Dana Farber Cancer Institute

74 trials at this site

First | Previous | Page 3 of 4 | Next | Last